<i>N,N</i>-Dimethyl-2-(trimethylsilyl)acetamide

Larson, Gerald L.

doi:10.1002/047084289x.rd395

Cited by 1 publication

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…71 The combination of 2P-PTX/2P-GEM provided the highest tumor growth inhibition efficacy as a result of synergism of this combination. 19,49 Other combination systems using HPMA copolymer carriers have also shown enhanced activity when compared to monotherapy. 47,48,50,72…”

Section: Discussionmentioning

confidence: 99%

“…Researchers studied the relationship between the detailed structure of HPMA copolymer-drug conjugates on one hand and their physicochemical and biological properties on the other hand. The impacts of architecture, 25,[40][41][42] structure of spacer between drug and carrier, 3,25,43,44 solution properties (aggregation), 45,46 combination therapy, [47][48][49] targeting stem cells, 50 multivalency, 12,51 and hyperthermia 52 were evaluated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts

et al. 2017

View full text Add to dashboard Cite

Degradable diblock and multiblock (tetrablock and hexablock) N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-gemcitabine (GEM) and -paclitaxel (PTX) conjugates were synthesized by reversible addition-fragmentation chain-transter (RAFT) copolymerization followed by click reaction for preclinical investigation. The aim was to validate the hypothesis that long-circulating conjugates are needed to generate a sustained concentration gradient between vasculature and a solid tumor and result in significant anticancer effect. To evaluate the impact of molecular weight of the conjugates on treatment efficacy, diblock, tetrablock, and hexablock GEM and PTX conjugates were administered intravenously to nude mice bearing A2780 human ovarian xenografts. For GEM conjugates, triple doses with dosage 5 mg/kg were given on days 0, 7, and 14 (q7dx3), whereas a single dose regime with 20 mg/kg was applied on day 0 for PTX conjugates treatment. The most effective conjugates for each monotherapy were the diblock ones, 2P-GEM and 2P-PTX (Mw ≈ 100 kDa). Increasing the Mw to 200 or 300 kDa resulted in decrease of activity most probably due to changes in the conformation of the macromolecule because of interaction of hydrophobic residues at side chain termini and formation of "unimer micelles". In addition to monotherapy, a sequential combination treatment of diblock PTX conjugate followed by GEM conjugate (2P-PTX/2P-GEM) was also performed, which showed the best tumor growth inhibition due to synergistic effect: complete remission was achieved after the first treatment cycle. However, because of low dose applied, tumor recurrence was observed 2 weeks after cease of treatment. To assess optimal route of administration, intraperitoneal (i.p.) application of 2P-GEM, 2P-PTX, and their combination was examined. The fact that the highest anticancer efficiency was achieved with diblock conjugates that can be synthesized in one scalable step bodes well for the translation into clinics.

show abstract

Section: Discussionmentioning

confidence: 99%